All In Biotech

Drug Trial Radar · NCT06034470

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Dec 18, 2023

Primary completion

May 31, 2026

Study completion May 31, 2029

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination therapy in treating patients with newly diagnosed adverse risk acute myeloid leukemia (AML) and other high-grade myeloid neoplasms. PVEK is a monoclonal antibody linked to a chemotherapy drug. PVEK is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD123 receptors, and delivers the chemotherapy drug to kill them. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. Giving PVEK with the FLAG-Ida regimen may be a safe and effective treatment for patients with acute myeloid leukemia and other high-grade myeloid neoplasms.

Conditions

  • Acute Myeloid Leukemia
  • Mixed Phenotype Acute Leukemia
  • Myelodysplastic Syndrome
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Myeloproliferative Neoplasm

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspirate

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • CytarabineDrug

    Given IV

  • EchocardiographyProcedure

    Undergo ECHO

  • FludarabineDrug

    Given IV

  • Granulocyte Colony-Stimulating FactorDrug

    Given SC

  • IdarubicinDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA scan

  • Pivekimab SunirineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities during cycle 1Time frame: During cycle 1 on day 42, or the start of the next cycle

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.